Rights issue 2026

Klaria carries out a rights issue of up to approximately SEK 147.6 million to strengthen its financial position ahead of an exciting commercial phase.

Klaria's licensing partner CNX Therapeutics is expected to launch the company's market-approved product Sumatriptan Alginate Film in Europe in the near future, and together with BDO, strategic alternatives (including for the US market) are being evaluated to maximize shareholder value.

Read more on the issue page (opens in new tab)

Documents